CAMBRIDGE, Mass.--( BUSINESS WIRE )--AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced the pricing of its previously announced underwritten public

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO ) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced it has commenced an underwritten public offering of

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 2:10 p.m. BST .

- Data presented during poster session at the AACR 2019 Annual Meeting - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2019-- AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO’s potent hepatocyte

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 14, 2019-- AVEO Oncology (NASDAQ: AVEO ) today reported financial results for the full year ended December 31, 2018 and provided a business update. “The results of TIVO -3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and

- John H. Johnson to Step Down from Board; Will Remain an Advisor to the Company - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of Gregory T. Mayes to its Board of Directors. Mr. Mayes brings to the AVEO Board over 20 years of

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 16, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO -3 study of tivozanib (FOTIVDA ® ) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC).

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration ( FDA ) not to submit a New Drug Application (NDA) for tivozanib (FOTIVDA®) with the preliminary overall survival (OS)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that data from the Phase 3 TIVO -3 study of tivozanib (FOTIVDA ® ) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019

Phase 1/2 Study will Evaluate Combination of IMFINZI ® (durvalumab) and FOTIVDA ® (tivozanib) in First-Line HCC CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 12, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety

Extends Cash Runway to Fund Planned Operations into the Third Quarter of 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA ® (tivozanib) as a first line

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2018 and provided a business update. “The recent announcement of positive topline results from the Phase 3 TIVO -3 study in renal cell carcinoma

- First and Only Positive Phase 3 Study in Third- and Fourth-Line RCC - - Primary Endpoint Shows 44% Improvement in Median PFS and 26% Reduction in Risk of Progression or Death (HR=0.74, p=0.02) for Tivozanib Compared to Sorafenib - - Data for Secondary Endpoint of Overall Survival Not Yet Mature;

Tivozanib-Nivolumab Combination Continues to Demonstrate Favorable Efficacy and Safety Data Presented at the European Society of Medical Oncology ( ESMO ) 2018 Annual Congress CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Oct. 22, 2018-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 9, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO ® ) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology

- Analysis Initiated on the Unanimous Recommendation of the TIVO -3 Study Independent Steering Committee - - Company Expects to Report Topline Results in Approximately 6 Weeks - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has initiated

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2018-- AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the following investor conferences: 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 28, 2018-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO ) today announced that Michael Bailey , president and chief executive officer, will participate in the following investor conferences: B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 17, 2018-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO ) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018 ,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 16, 2018-- AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or

- IND acceptance triggers $2M milestone payment from CANbridge to AVEO - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 14, 2018-- AVEO Oncology (Nasdaq: AVEO ) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “Our U.S. registration strategy remains a key focus for AVEO , with topline readout of the Phase 3 TIVO -3 study

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 19, 2018-- AVEO Oncology (NASDAQ: AVEO ) today issued the following statement regarding its recently revised guidance on the timing of topline data from the TIVO -3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has been added to the Russell 2000 ® , Russell 3000 ® , and Russell Microcap ® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 31, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2018 and provided a business update. “We continue to work toward reporting topline results from our Phase 3 TIVO -3 Study, which we now anticipate

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the following investor conferences: Needham & Company’s 17th Annual Healthcare Conference on Wednesday, March 28, 2018 at 8:00

Results Published in the European Journal of Cancer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 21, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib (FOTIVDA ® ) as second-line treatment in

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2018-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2017 and provided a business update. “Last year was one of major progress for AVEO , with highlights including the first commercial launch of

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the Cowen and Company 38 th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m. Eastern Time .

Recommendation Triggers $2M Milestone Payment from EUSA to AVEO CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD)

Data Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Feb. 10, 2018-- AVEO Oncology (NASDAQ: AVEO ) and EUSA Pharma today announced the presentation of preliminary results from the

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the following investor conferences: LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2018-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held

Poster Presentation Delivered at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 19, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA ®

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time .

Provides Approximately $12.1M in Additional Cash Flow Over 2018-19 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc.

- Enrollment complete in Phase 2 portion of Phase 1/2 TiNivo trial; Next data presentation expected at 2018 Genitourinary Cancers Symposium in February 2018 - - Investigator-sponsored studies of ficlatuzumab initiated in HNSCC and Pancreatic Cancer - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of Nikhil Mehta , Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017 . In this role, Dr. Mehta will oversee all aspects of regulatory,

HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2017-- EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA ® (tivozanib) with the initiation of product sales in Germany . In the European Union , Norway and Iceland , tivozanib is

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will be presenting at the following investor conferences: Jefferies 2017 London Healthcare Conference on Wednesday, November 15, 2017 at 4:00

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2017 and provided a business update. “The third quarter was a transformative period for AVEO , with the achievement of significant milestones in

Oral Presentation Delivered at the 16 th International Kidney Cancer Symposium CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Nov. 6, 2017-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 16, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 5, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO -3 trial, the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA ® (tivozanib) to sorafenib in

Exercise of Option Triggers $2.0 Million Research and Development Payment to AVEO CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Sep. 20, 2017-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA ® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma in

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will be presenting at the following investor conferences: The 19 th Annual Rodman & Renshaw Global Investment Conference on Tuesday,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 28, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that the European Commission (EC) has approved FOTIVDA ® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2017 , and provided a business update. “The second quarter was marked by validating events in each of the three pillars of our global tivozanib

Additional Resources Sufficient to Fund Planned Operations into the 4Q 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 27, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that it has secured $14 million in aggregate gross proceeds through its credit facility with Hercules Capital, Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment for

– Pre-planned futility analysis of the trial expected midyear 2017; topline data expected in the first quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 20, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that the Company’s pivotal TIVO -3 trial, a randomized, controlled,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that its Phase 1/2 AVEO -sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo ® (nivolumab), in subjects with advanced renal cell carcinoma

Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Announces Trial in Progress Poster Also Presented Highlighting Phase 3 TIVO -3 Study of Tivozanib in RCC CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 19, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 16, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017 . In this role, Mr. Dallas will be responsible for the Company’s financial strategy and management as it takes steps

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2017-- The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today issued the following statement regarding the passing of its Lead Director Henri A. Termeer . “We are deeply saddened at the loss of a visionary, mentor, colleague and dear friend, Henri A.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/653,684, entitled "notch binding agents and antagonists and methods

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017 , and provided a business update. “We strengthened our balance sheet in the first quarter through an underwritten public offering, giving us the

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology ( ASCO ) Annual Meeting, held June 2-6, 2017 .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 13, 2017-- AVEO Oncology (NASDAQ: AVEO ) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the Marketing Authorization

Company Provides Updated Financial Guidance CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd. , a biopharmaceutical company focused on developing western drug candidates in China

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its option to purchase

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 28, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.50 per share, before underwriting discounts, which would result in

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 28, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update. “TIVO-3, our lead clinical program designed to serve as the basis for a potential U.S.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO -sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 23, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO -3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), has

- Pivotal TIVO-3 Trial Enrollment Proceeding Substantially Ahead of Schedule; Enrollment Completion Expected in June - - Phase 1/2 TiNivo Trial Sites Scheduled to Open for Enrollment in Early March - - Partner EUSA Pharma Receives Day 180 List of Outstanding Issues from EMA, Oral Explanation

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 6, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle , M.D., Chief Medical Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017 at 8:30 AM E.T.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 28, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European Medicines Agency (EMA) Day

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 22, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 28 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 3:30 PM Eastern Time .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016 . “In the last 18 months, we have made important progress in moving forward both elements of our strategy, including our oncology pipeline,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 12, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 30, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.m. , before the Honorable Denise J. Casper , United States Courthouse , Courtroom No. 11 of the John Joseph Moakley U.S.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 18 th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 12:30 PM Eastern Time .

- Phase 1/2 TiNivo Trial to Commence at the Institut Gustave Roussy in Paris - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016 . “The second quarter of 2016 marked a defining moment for AVEO , with the initiation of TIVO -3, our Phase 3 pivotal study of tivozanib in

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle , M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 26, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company’s pivotal TIVO -3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory

Private Placement Provides Gross Proceeds of Approximately $17 Million ; Amended Term Loan to Provide up to $10 Million in Funding CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 10, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016 . “We achieved several important goals in the first quarter critical to advancing the corporate strategy we outlined early in 2015.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company’s potent inhibitory antibody

CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Mar. 21, 2016-- AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia , today announced an exclusive collaboration and license agreement in which

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update. “Over the course of 2015, AVEO has streamlined its organization and taken a fresh strategic direction to create

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016 , at 9:00 a.m. Pacific Time .

HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2016-- EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 22, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma (“RCC”) has been accepted by the Ministry of Health (“MoH”)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 , at 9:00 a.m. Eastern Time .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San Francisco .

EUSA to Submit Marketing Authorization Application for Tivozanib in Advanced RCC in Q1 2016 AVEO to Host Conference Call Today, December 21, 2015 at 9:00 AM ET CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England --(BUSINESS WIRE)--Dec. 21, 2015-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update. “We completed partnerships for two of AVEO’s lead programs in the third quarter in addition to making

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc , after 13 years of service and leadership at AVEO , has stepped down as Chairman and a Director of the Company’s board of directors, effective November 6, 2015 , to pursue interests

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 17, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor

Company to Host Midyear Update Conference Call Today, August 10 at 10:00 am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 10, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015 . “The second quarter was productive on multiple fronts for AVEO

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015 , at 10:00 a.m. Eastern Time to provide an update on recent developments and corporate goals, as well as discuss financial results

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group , the largest Russian pharmaceutical group (“Pharmstandard”), for the development, manufacturing and

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 30, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- ( B iomarker A ssessment of T ivozanib in ON cology) CRC study will be presented at the European Society for Medical Oncology (ESMO) 17 th World

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 11, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC).

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of renal cell carcinoma (RCC),

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New York City .

Unveils New Corporate Logo CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 26, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts , effective today. Consistent with the Company’s goal of streamlining operations to

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 20, 2015-- AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO -1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015 . “We continue to execute on our strategy of leveraging biomarker insights and exploring partnership opportunities to advance our pipeline, while

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 22, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company’s financial and administrative strategy and management, and

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2014 . “At the beginning of 2015, AVEO implemented several important changes designed to maximize the value of our portfolio of clinical stage

Results Presented at AACR Tumor Angiogenesis and Vascular Normalization Conference AVEO to Host Conference Call Today, March 6, 2015 at 8:00 am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of final results, including a predefined

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015 , at 8:00 a.m. Eastern Time to discuss the presentation of final results and a predefined biomarker analysis of its

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 12, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey , president and chief executive officer, will present at the 33 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle , M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating

Company to Evaluate Potential for Submission of a Tivozanib MAA for the Treatment of RCC CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for

Michael P. Bailey Named President and Chief Executive Officer; Tuan Ha-Ngoc Named Chairman of the Board Company to Eliminate Internal Research Function to Align Corporate Resources with the Company’s Future Strategic Plans CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 11, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation , under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan. “At AVEO, we continue to execute on all aspects of our strategic plan.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for

VeriStrat “Poor” Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End MADRID --(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective

MONTREAL --(BUSINESS WIRE)--Sep. 26, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 26, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company’s headquarters in Cambridge, Massachusetts ,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 17, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and

Ficlatuzumab Phase 2 NSCLC Data and Tivozanib Phase 2 CRC and RCC Data to Be Presented at ESMO 2014 Congress AV-380 Preclinical Data to Be Presented at 2nd Cancer Cachexia Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 11, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its second quarter

CAMBRIDGE, Mass. & CHICAGO --(BUSINESS WIRE)--May 31, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 28, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc , chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “We made solid progress executing on a key component of our recently announced corporate

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2014-- AVEO Oncology (NASDAQ: AVEO ) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014 . Management plans to host financial results conference calls

Biodesix to Fund Proof of Concept Study CAMBRIDGE, Mass. & BOULDER, Colo. --(BUSINESS WIRE)--Apr. 10, 2014-- AVEO Oncology (NASDAQ: AVEO ) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF)

Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2014-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate,

- Company ends 2013 with $118M in cash 1 - - Focuses internal R&D investment on AV-380 in cachexia - - Intends to advance clinical-stage assets through strategic partnering – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2014-- AVEO Oncology (NASDAQ: AVEO ) today reported consolidated 2013

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2014-- AVEO Oncology (NASDAQ: AVEO ) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014 .

Phase 2 Colorectal Cancer Study Discontinued AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014 CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Feb. 14, 2014-- AVEO Oncology (NASDAQ: AVEO ) and Astellas Pharma Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 30, 2014-- AVEO Oncology (NASDAQ: AVEO ) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON ( B iomarker  A ssessment of  T ivozanib in  ON cology) breast cancer clinical trial, a Phase 2 study in patients with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 13, 2013-- AVEO Oncology (NASDAQ: AVEO ) today announced that data from a planned interim analysis of the Phase 2 BATON ( B iomarker  A ssessment of  T ivozanib in  ON cology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results. “We continue to execute on the strategy we outlined earlier this year, focusing our resources where the unique insights derived from our proprietary Human

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc , chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.m. (ET) in New York City .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Canaccord Genuity 33 rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.m. (ET) in Boston .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results. “We are moving forward as an organization and are firmly focused on executing our revised business strategy,” said Tuan Ha-Ngoc , president and chief executive

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 10, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration ( FDA ) informing the company that the FDA will not approve in its present form the New Drug Application (NDA)

AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring that will refocus the company’s efforts and resources on the ongoing clinical development of tivozanib in

CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--May. 15, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO -1 trial ( TI vozanib V ersus s O rafenib in 1 st line advanced RCC) of investigational agent tivozanib in

CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--May. 2, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s ( FDA ) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent

FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma AVEO Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 2, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that NASDAQ halted trading of AVEO common stock this morning, May

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported first quarter 2013 financial results. In lieu of a quarterly financial update conference call, the AVEO management team expects to host a conference call on May 2, 2013 following the review by the U.S.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.m. (ET) in Miami .

Oncologic Drugs Advisory Committee Meeting Scheduled for May 2, 2013 CAMBRIDGE, Mass. & NORTHBROOK, Ill. --(BUSINESS WIRE)--Feb. 27, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc. , a U.S. subsidiary of Tokyo -based Astellas Pharma Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.m. (ET) in New York City .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2013-- AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2012 financial results and reviewed key recent accomplishments. “We continue to make significant progress with tivozanib, including reporting the final overall survival results from TIVO -1,

Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Feb. 12, 2013-- AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2013-- AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013 .

CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Jan. 29, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock. The total number of shares sold was 7,667,050, comprised of 6,667,000 shares of common stock initially offered and

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 22, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of the option granted to the

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 17, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.50 per share to the public. All of the shares are being sold by AVEO.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 16, 2013-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO. J.P.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 27, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc , president and chief executive officer, is scheduled to present at the 31 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013 at 11:00 a.m. (PT) in San Francisco .

Ronald A. DePinho , M.D. Retires from AVEO Board of Directors CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 20, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Robert Epstein , M.D., M.S. to its Board of Directors, and that Ronald A. DePinho, M.D.

BATON-BC Trial Initiation Marks Entry into Third Tumor Type for Tivozanib Clinical Development Program CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Dec. 3, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a

CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Nov. 28, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for filing the New Drug Application (NDA) for tivozanib with the proposed indication for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 26, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST Conference on Monday, December 3, 2012 at 4:35 p.m. (ET) in Boston .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 6, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 1:00 p.m. (ET) in New York City .

Refocused Resources Projected to Save $100 Million over Three Years Progress Made toward Commercialization of Tivozanib CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 30, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring designed to optimize resources and reduce expenses to

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2012 will be released before the market opens on Tuesday, October 30, 2012 . The AVEO management team will host a conference

First Patient Enrolled in TAURUS Patient Preference Study Posters 795PD, 796PD and 892TiP CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Oct. 1, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO -1 trial ( TI vozanib V ersus s O

Ficlatuzumab Phase 1 Pharmacodynamic Data Also Presented CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company’s HGF inhibitory

CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Sep. 28, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) seeking approval for tivozanib in patients with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that new clinical data on its lead product candidate tivozanib, partnered with Astellas Pharma Inc. (TSE: 4503), as well as its HGF inhibitory antibody ficlatuzumab will be presented at the European

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the UBS Annual Global Life Sciences Conference on Thursday, September 20, 2012 at 2:00 p.m. (ET) in New York City .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 10, 2012 at 10:35 a.m. (ET) in New York City .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Canaccord Genuity 32 nd Annual Growth Conference on Thursday, August 16, 2012 at 10:00 a.m. (ET) in Boston .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2012-- AVEO Oncology (NASDAQ: AVEO) today reported consolidated financial results for the second quarter of 2012, and highlighted recent developments and key second quarter accomplishments. “The last six months have been very productive for AVEO Oncology,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 26, 2012-- AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's second quarter ended June 30, 2012 will be released before the market opens on Thursday, August 2, 2012 . The AVEO management team will host a conference call

Study designed to build upon safety profile demonstrated in TIVO -1 study CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Jun. 4, 2012-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS ( T ivoz A nib U se ve R s U s S

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 30, 2012-- AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.m. (CT) to review the Phase 3 TIVO -1 data that will be presented at the 2012 Annual Meeting of the American

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 29, 2012-- AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston , chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 3:00 p.m. (ET) in New York City .

AV-203 is the Third AVEO Molecule to Enter Clinic CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 23, 2012-- AVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced

- Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment - - First Pivotal Trial vs. Active Targeted Agent in First-Line Advanced RCC - - Study Results Demonstrate Unique Combination of Superior PFS and Favorable Tolerability - CAMBRIDGE,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 3, 2012-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the first quarter of 2012 and reviewed key first quarter accomplishments. “Since the achievement of the primary endpoint in our TIVO -1 study early in the

Ficlatuzumab/Gefitinib Combination Was Well-Tolerated and Demonstrated Clinical Activity; Study Results Did Not Reach Statistical Significance Encouraging Signals of Anti-tumor Activity in Distinct Subpopulations CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 2, 2012-- AVEO Pharmaceuticals Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences. Tuan Ha-Ngoc , president and chief executive officer, is scheduled to present at the

CAMBRIDGE, Mass., Apr 26, 2012 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's first quarter ended March 31, 2012 will be released before the market opens on Thursday, May 3, 2012. The AVEO management team will host a conference

Tivozanib Demonstrated Improved Median Progression-Free Survival Combined with a Well Tolerated Safety Profile in Patients with Advanced Renal Cell Carcinoma CAMBRIDGE, Mass., Apr 12, 2012 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported results

AVEO’s Novel, Internally-Discovered ErbB3 Inhibitory Antibody, AV-203, Entering Clinic This Year CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 27, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2012-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc , president and chief executive officer, is scheduled to present at the Cowen and Company 32 nd Annual Health Care Conference on Monday, March 5, 2012 at 4:10 p.m.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today reported consolidated 2011 financial results and reviewed key progress achieved with its tivozanib and ficlatuzumab development programs in the fourth quarter of 2011.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2011 will be released before the market opens on Tuesday, February 14, 2012 .

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that members of the company’s management team are scheduled to present a corporate overview at several upcoming investment conferences. The conference and AVEO presentation details are as

TIVO -1 is the First Registration Trial to Compare an Investigational Agent to an Approved VEGF Therapy in First-line RCC AVEO Conference Call Today at 8:30 a.m. ET CAMBRIDGE, Mass. & TOKYO --(BUSINESS WIRE)--Jan. 3, 2012-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Astellas Pharma Inc.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. (ET) . The call can be accessed by dialing 1-866-825-3354 (domestic) or 1-617-213-8063

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 28, 2011-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc , president and chief executive officer, is scheduled to present at the 30 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2012 at 11:30 a.m.

The Trial, BATON-CRC, is Second in Series of Tivozanib Biomarker Trials CAMBRIDGE, MASS .--(BUSINESS WIRE)--Dec. 22, 2011-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called

CAMBRIDGE, Mass. & INGELHEIM, Germany --(BUSINESS WIRE)--Dec. 1, 2011-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s novel HGF

Tivozanib Highlighted at EMUC 2011; New Data Featured at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference CAMBRIDGE, Mass., Nov 03, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported clinical data evaluating its lead product

Company Provides Update on Tivozanib Clinical Program and Timelines CAMBRIDGE, Mass., Nov 02, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

CAMBRIDGE, Mass., Oct 26, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's third quarter ended September 30, 2011 will be released before the market opens on Wednesday, November 2, 2011.

CAMBRIDGE, Mass., Aug 31, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the company's management will present a company overview at upcoming investment conferences. David Johnston, chief financial officer, is scheduled to present at the William Blair 2011

CAMBRIDGE, Mass., Aug 02, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Canaccord Genuity 31 st Annual Growth Conference on Tuesday, August 9, 2011 at 8:30 a.m.

CAMBRIDGE, Mass., Jul 28, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reviewed key second quarter accomplishments and reported consolidated financial results for the second quarter of 2011. "We are very pleased with the progress we have made against our corporate goals

CAMBRIDGE, Mass., Jul 21, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company's second quarter ended June 30, 2011 will be released before the market opens on Thursday, July 28, 2011.

CAMBRIDGE, Mass., Jun 21, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has closed its previously announced underwritten public offering of common stock. The total number of shares sold was 6,352,119, comprised of 5,750,000 shares of common stock

CAMBRIDGE, Mass., Jun 15, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 5,750,000 shares of its common stock at a price of $17.50 per share to the public. All of the shares are being sold by AVEO.

CAMBRIDGE, Mass., Jun 14, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO. J.P.

Ongoing Ficlatuzumab Phase 2 Trial Highlighted at ASCO; Patient Enrollment Completed CAMBRIDGE, Mass. & CHICAGO, Jun 02, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in

Median PFS Was 11.7 Months among All Treated Patients and 14.8 Months among Those with Clear Cell RCC Who Had Undergone Nephrectomy; Phase 1 Combination Data in RCC and Breast Cancer Also Presented CAMBRIDGE, Mass. & CHICAGO, Jun 02, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc.

CAMBRIDGE, Mass., May 31, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting

CAMBRIDGE, Mass., May 27, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 10:30 a.m.

CAMBRIDGE, Mass., May 18, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that clinical data evaluating tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and ficlatuzumab (formerly AV-299),

CAMBRIDGE, Mass., Apr 28, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reviewed key first quarter accomplishments and reported consolidated financial results for the first quarter of 2011. "AVEO began 2011 with significant momentum with the commencement of our

CAMBRIDGE, Mass., Apr 26, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Deutsche Bank Securities 36 th Annual Health Care Conference on Tuesday, May 3, 2011 at 2:50 p.m.

CAMBRIDGE, Mass., Apr 21, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company's first quarter ended March 31, 2011 will be released before the market opens on Thursday, April 28, 2011.

CAMBRIDGE, Mass., Apr 12, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the appointment of industry veteran Henri A. Termeer, outgoing chairman, president and chief executive officer of Genzyme Corporation, to its Board of Directors.

CAMBRIDGE, Mass., Mar 31, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to participate in a panel titled "Prostate and GU Cancers" at 12:15 p.m.

CAMBRIDGE, Mass., Mar 28, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody

CAMBRIDGE, Mass., Feb 23, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced that members of the company's management team are scheduled to present a corporate overview at several upcoming investment conferences. The conference and AVEO presentation details are as

CAMBRIDGE, Mass., Feb 16, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated 2010 financial results and reviewed key 2010 accomplishments.

-- AVEO to Receive $125 Million Upfront and $1.3 Billion in Potential Milestones -- -- Global 50/50 Profit Share with AVEO to Lead Commercialization in North America and Astellas to Lead Commercialization in Europe -- -- Agreement Accelerates Development of Tivozanib in Multiple Additional Cancer

CAMBRIDGE, Mass., Feb 14, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in

CAMBRIDGE, Mass., Feb 10, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2010 will be released after the market closes on Wednesday, February 16, 2011.

CAMBRIDGE, Mass., Feb 03, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the

CAMBRIDGE, Mass., Feb 01, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by

CAMBRIDGE, Mass., Jan 21, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive data from its Phase 1b clinical trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three

CAMBRIDGE, Mass., Jan 04, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 29 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10:00 a.m.

Data Underscore Potential for Tivozanib to be Safely Combined with Other Anti-Cancer Agents CAMBRIDGE, Mass. & SAN ANTONIO, Dec 10, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer

CAMBRIDGE, Mass., Dec 02, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product

Option Triggers $25 Million in Milestone Payments to AVEO MELVILLE, N.Y. & TOKYO & CAMBRIDGE, MASS., Dec 01, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc., ("OSI"), which is a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., and

CAMBRIDGE, Mass., Nov 22, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company's management will present a company overview at several upcoming

Preclinical Data from the Company's FGFR Antibody Program also Presented CAMBRIDGE, Mass. & BERLIN, Nov 19, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced

Preclinical Data Presented Demonstrates that Combining Tivozanib with Chemotherapy Regimens Inhibits Breast Tumor Growth and Prevents Development of Resistance CAMBRIDGE, Mass. & BERLIN, Nov 18, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company

Trial to Evaluate Tivozanib in Combination with Widely-Used Oral Xeloda ® in Patients with Advanced Breast and Colorectal Cancers CAMBRIDGE, Mass., Nov 16, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and

Tivozanib Data Also Presented at Annual Chemotherapy Foundation Symposium CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new

Current Financial Position Supports Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Nov 04, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer

AVEO to Present at Windhover's Annual Therapeutic Area Partnerships Meeting CAMBRIDGE, Mass., Nov 03, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that its

Proceeds to Fund Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Oct 29, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced

CAMBRIDGE, Mass., Oct 21, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company's third quarter ended September 30, 2010 will

CAMBRIDGE, Mass. & MILAN, Oct 11, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib

Tivozanib Clinical Data and Pipeline Overview Presented CAMBRIDGE, Mass., Oct 01, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported

CAMBRIDGE, Mass., Sep 30, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering

CAMBRIDGE, Mass., Sep 28, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company will have a presence at two upcoming oncology medical meetings and

Company Enhances Leadership Team and Prepares for Forward Integration CAMBRIDGE, Mass., Sep 13, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the appointment

CAMBRIDGE, Mass., Sep 02, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company's management will present at several upcoming investment conferences.

CAMBRIDGE, Mass. Aug 12, 2010 -- (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical

CAMBRIDGE, Mass., Aug 05, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at

AVEO's Patented Tivozanib Biomarker Highlighted as Part of IBC's Drug Discovery & Development Week CAMBRIDGE, Mass., Aug 02, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics,

Advancement of Innovative Pipeline; Achievement of Collaboration-Driven Milestone CAMBRIDGE, Mass., Jul 29, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an

CAMBRIDGE, Mass., Jul 22, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company's second quarter ended June 30, 2010 will be

CAMBRIDGE, Mass., Jun 30, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the publication of a cover article in the current issue of Nature Reviews Cancer

CAMBRIDGE, Mass., Jun 29, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company has been added to the Russell 2000(R) Index, as part of the annual

Designation Reinforces Opportunity for Safe and Effective Treatment Option for Renal Cell Cancer CAMBRIDGE, Mass., Jun 24, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today

CAMBRIDGE, Mass., Jun 21, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer of AVEO, will close the NASDAQ

AVEO's Human Response Platform(TM) Enables Discovery of Biomarkers to Predict Patient Response CAMBRIDGE, Mass., Jun 16, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today

Additional Phase 2 Data Presented at ASCO; Phase 3 TIVO-1 Trial Underway to Evaluate Tivozanib's Efficacy and Safety Profile CAMBRIDGE, Mass. & CHICAGO, Jun 07, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and

Results of Phase 1 Trial Presented at ASCO Annual Meeting CAMBRIDGE, Mass., Jun 05, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase

CAMBRIDGE, Mass., Jun 02, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the

Additional Analyses from Phase 2 Trial of Tivozanib and Phase 1 AV-299 Data to be Presented CAMBRIDGE, Mass., May 20, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today

Significant Progress in Development of Lead Product Candidate Tivozanib; 2010 Financial Guidance Provided CAMBRIDGE, Mass., Apr 29, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer

CAMBRIDGE, Mass., Apr 22, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company's first quarter ended March 31, 2010 will be

Data Presented at AACR 101 st Annual Meeting 2010; Confirm Potential Utility of AVEO's Antibody Pipeline CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer

Milestone Achieved Through Selection of First ErbB3 Antibody Development Candidate CAMBRIDGE, Mass., Apr 14, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it

CAMBRIDGE, Mass., Apr 13, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline

CAMBRIDGE, Mass., April 1, 2010 --(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO - News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of

CAMBRIDGE, Mass., Mar 18, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock.

CAMBRIDGE, Mass., Mar 11, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at

CAMBRIDGE, Mass., February 22, 2010 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has initiated enrollment in a global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor,

CAMBRIDGE, Mass., December 16, 2009—AVEO Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock.

Preclinical Combination Data Also Presented, Demonstrate mTOR-Tivozanib Combination in Breast Tumor Model Prevents Emergence of Resistance CAMBRIDGE, Mass., November 17, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer

CAMBRIDGE, Mass., September 16, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of William J.

CAMBRIDGE, Mass., September 4, 2009 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Rodman & Renshaw 11th Annual Healthcare Conference on Friday, September 11, 2009 at 10:50 a.m.

CAMBRIDGE, Mass., August 4, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference on Tuesday, August 11, 2009 at 3:00 p.m. (EDT) at the InterContinental Hotel in Boston, Mass.

Preclinical Data Presented at International Lung Conference; Underscores Tivozanib Potency CAMBRIDGE, Mass., July 31, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology

CAMBRIDGE, Mass., July 30, 2009 – AVEO Pharmaceuticals, Inc. today announced that Murray Robinson, Ph.D., senior vice president, oncology, is scheduled to present at IBC’s New Frontiers in Cancer Drug Development Conference on Tuesday, August 4, 2009 at 1:40 p.m.

MELVILLE, NY and CAMBRIDGE, Mass., July 21, 2009 – OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and AVEO Pharmaceuticals, Inc. today announced that they have expanded the drug discovery and translational research collaboration announced in October of 2007.

Novel Technology Allows Rapid Production of Genetically Defined In Vivo Tumor Models CAMBRIDGE, Mass., July 8, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies,

- Discovery of HeyL Gene Expression as Biomarker Marks Critical Step in Developing Targeted Therapeutics to Inhibit Notch Pathway - CAMBRIDGE, Mass., June 17, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop

CAMBRIDGE, Mass., June 5, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the 8th Annual Needham & Company Life Sciences Conference on Thursday, June 11, 2009 at 9:00 a.m. (EDT) at the New York Palace Hotel in New York

Results Show Median Progression-Free Survival of 11.8 Months; Tivozanib Designated as Generic Name for AV-951 CAMBRIDGE, Mass., May 29, 2009> – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize

Progression-free Survival Data from AV-951 Phase 2 Trial in Advanced Kidney Cancer to be Highlighted at ASCO CAMBRIDGE, Mass., May 18, 2009– AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted

SAB Members Elected to NAS and IOM; Honored with Awards from AACR and NFCR CAMBRIDGE, Mass., May 13, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today

Data Presented at AACR Annual Meeting; Suggests Additional Therapeutic Potential for AV-951 DENVER, Col., April 21, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology

FGFR-2 Target Identification and Response Data Also Highlighted; Data Presented at AACR Annual Meeting DENVER, Col, April 19, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology

CAMBRIDGE, Mass., April 9, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it will present during two educational sessions, nine poster

AVEO Scientists Generate Human Tumors in Mice from Primary Human Breast Tissue; Provides More Realistic Genetic Context in which to Evaluate New Anti-tumor Therapies CAMBRIDGE, Mass., April 6, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in

CAMBRIDGE, Mass., March 26, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Future Leaders in the Biotech Industry Conference on Thursday, April 2, 2009 at 1:30 p.m. (EDT) at the Millennium Broadway Hotel & Conference

Biogen Idec to Obtain Option to Commercialize ErbB3 Antibodies Outside of North America CAMBRIDGE, Mass., March 24, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology

Cambridge, Mass., March 23, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that Tuan Ha-Ngoc, president and chief executive officer, will present

Biogen Idec to Obtain Option to Commercialize ErbB3 Antibodies Outside of North America CAMBRIDGE, Mass., March 24, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology

CAMBRIDGE, Mass., March 11, 2009 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 9:30 a.m.

CAMBRIDGE, Mass., March 10, 2009 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the initiation of a Phase 1b/2a clinical trial of AV-951 as monotherapy

CAMBRIDGE, Mass., March 6, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Barclays Global Healthcare Conference on Tuesday, March 10, 2009 at 4:15 p.m. (EDT) at the Loews Miami Beach Hotel in Miami, FL.

272-Patient Phase 2 Data Show 91.7 Percent Disease Control Rate and Favorable Tolerability; Interim Results Being Presented at ASCO GU Indicate Highly Differentiated VEGFR Profile CAMBRIDGE, Mass., February 25, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough

CAMBRIDGE, Mass., February 19, 2009 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the initiation of a Phase 1b/2a clinical trial in breast cancer,

CAMBRIDGE, Mass., February 12, 2009 – AVEO Pharmaceuticals, Inc. today announced that M. Isabel Chiu, Ph.D., vice president, translational research, will lead a session for the Mass Biotechnology Council’s (MBC) Drug Discovery Committee on Thursday, February 19, 2009 at 8:00 a.m.

CAMBRIDGE, Mass., February 11, 2009 – AVEO Pharmaceuticals, Inc. today announced that interim safety and efficacy results from the Phase 2 clinical trial of its lead product AV-951 – a novel, highly potent and selective triple VEGF receptor inhibitor – will be presented during an oral abstract

CAMBRIDGE, Mass., January 6, 2009– AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 11:30 a.m. PST at the Westin St.

CAMBRIDGE, Mass., November 12, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Lazard Capital Markets Fifth Annual Healthcare Conference on Wednesday, November 19, 2008 at 11:30 a.m. (ET) at the St.

CAMBRIDGE, MA [October 20, 2008] – AVEO Pharmaceuticals today announced that Murray O. Robinson, Ph.D., senior vice president of oncology, will present at the 2008 Boston Biotech R&D Conference on Wednesday, October 22, 2008, 2:20 p.m. (ET) at Harvard Medical School.

CAMBRIDGE, Mass., September 30, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Third Annual JMP Securities Healthcare Focus Conference on Tuesday, October 7, 2008 at 3:00 p.m.

-- SCH900105 (AV-299) Marks First of Several Monoclonal Antibodies from AVEO’s Discovery Platform;  Trial Triggers Milestone Under Agreement with Schering Plough -- CAMBRIDGE, Mass., September 23, 2008 – AVEO Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial

CAMBRIDGE, Mass., August 25, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it has initiated another Phase 1b clinical study for its lead

Cambridge, MA, July 22, 2008 – Dyax Corp. (NASDAQ: DYAX) and AVEO Pharmaceuticals, Inc. announced today that Dyax has granted AVEO a non-exclusive license to Dyax’s proprietary antibody phage display libraries for the discovery and development of therapeutic antibodies.  Dyax’s human antibody

CAMBRIDGE, Mass., May 29, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that they have completed enrollment in their 200-patient Phase 2 clinical

- Novel Technology Has Identified Multiple Targets Yielding Rich Pipeline of High-Value Oncology Antibodies - CAMBRIDGE, Mass., May 22, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted

CAMBRIDGE, MA, May 15, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 2008 Citi Investment Research Global Health Care Conference on Thursday, May 22, 2008 at 11:00 a.m.

CAMBRIDGE, MA, May 2, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Leerink Swann Solid Tumors Roundtable Conference on Friday, May 9, 2008 at 10:20 a.m. (ET) at the Grand Hyatt in New York City.

Proprietary Human Response Platform Data Reveal Distinct Biomarkers Potentially Critical to Determining Treatment Success     SAN DIEGO, Calif and CAMBRIDGE, Mass, April 14, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer

Six Abstracts on AVEO’s Proprietary Human Response Platform Also to be Presented CAMBRIDGE, Mass., April 8, 2008 -- AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today

CAMBRIDGE, MA, March 20, 2008 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Future Leaders in the Biotech Industry Conference on Thursday, March 27, 2008 at 2:00 p.m. (ET) at the Millennium Broadway Hotel in New York City.

CAMBRIDGE, MA, March 12, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 28th Annual Health Care Conference on Wednesday, March 19, 2008 at 4:00 p.m.

CAMBRIDGE, MA, February 5, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 1:15 p.m.

CAMBRIDGE, MA, January 31, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it has initiated a Phase 1b clinical trial for its lead product

CAMBRIDGE, MA, January 30, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Merrill Lynch Nineteenth Annual Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 6, 2008 at

CAMBRIDGE, MA, January 3, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of Kenneth M.

CAMBRIDGE, MA, January 2, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the 26th   Annual JPMorgan Healthcare Conference on Tuesday, January 8, 2008 at 2:30 p.m. PT at the Westin St.

- Agreement Highlights Growing Interest in Novel Biology Platform that Identifies Clinical Response of Cancer Drugs- CAMBRIDGE, MA, December 4, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize

CAMBRIDGE, MA, November 20, 2007 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the Lazard Capital Markets 4th Annual Healthcare Conference on Tuesday, November 27, 2007 at 9:30 a.m.

AV-412 Has Potential to Address Drug Resistance in Non-Small Cell Lung and Breast Cancer CAMBRIDGE, MA, November 13, 2007 – AVEO Pharmaceuticals, Inc., today announced encouraging preclinical data that show the potential of AV-412, a novel next generation oral tyrosine kinase inhibitor, as a

Company Initiates Phase 2 Clinical Trial of AV-951 in Patients with RCC Cambridge, MA, November 6, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced

CAMBRIDGE, MA, October 30, 2007 – AVEO Pharmaceuticals, Inc., today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, 2007 at 9:50 a.m.

CAMBRIDGE, MA, November 1, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of David Johnston to the newly created position of Chief

October 2, 2007, Sydney, Australia and Cambridge, MA –   Peptech Limited (ASX: PTD) and AVEO Pharmaceuticals Inc. today announced they have entered into a non-exclusive research and commercialisation agreement in which AVEO will access Peptech’s SuperhumanisationTM technology to humanise

CAMBRIDGE, MA, August 9, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, announced it has successfully completed its multi-year collaborative agreement with Merck

CAMBRIDGE, MA, June 18, 2007– AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that its president and chief executive officer, Tuan Ha-Ngoc, has been awarded

Cambridge, MA – May 3, 2007 – AVEO Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced that it has closed a $53 million Series D financing.  Proceeds from this financing will be used to accelerate the

- AVEO Pharmaceuticals Success with Breast Cancer Mouse Model Presented Today at AACR - LOS ANGELES CAMBRIDGE, Mass.--April 18, 2007--AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, presented today findings from

Data Presented at the American Association for Cancer Research (AACR) Annual Meeting LOS ANGELES, CA, and CAMBRIDGE, MA, April 17, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced encouraging

- Data to be Featured in Five Oral Presentations and Seven Poster Sessions - CAMBRIDGE, MA April 12, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, announced today that it will present a total of 12 oral

- Company to Participate in Development and Commercialization - CAMBRIDGE, MA April 4, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has entered into an exclusive worldwide agreement with

AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio CAMBRIDGE, Mass. Jan. 04, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has acquired from Kirin Brewery Co., Ltd.

CAMBRIDGE, MA October 23, 2006 – AVEO Pharmaceuticals, Inc. (AVEO), a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that it has begun enrolling patients in a Phase I clinical study for AV-412, a next generation oral tyrosine kinase

- Contract Follows Successful Human Engineering™ of AV-299 -   Berkeley, CA and Cambridge, MA -- September 28th, 2006 – Xoma Ltd. (Nasdaq: XOMA) and AVEO Pharmaceuticals, Inc. (AVEO) today announced a $6 million agreement for XOMA to manufacture and supply AV-299, AVEO’s novel anti-HGF

CAMBRIDGE, MA (September 27, 2006) - The Web Marketing Association ("WMA") today announced that it has awarded its "Pharmaceutical Industry Standard of Excellence" WebAward for 2006 to AVEO Pharmaceuticals - a biopharmaceutical company focused on the discovery and development of novel cancer

- Human Engineering™ Technology to Accelerate Development of Clinical Candidate -   Berkeley, CA and Cambridge, MA -- April 27, 2006 -- XOMA Ltd. (Nasdaq: XOMA) and AVEO Pharmaceuticals, Inc. (AVEO) today announced an agreement for XOMA to utilize its Human Engineering™ (HE™) technology to

- Human-in-Mouse (HIM) system represents breakthrough in modeling of human breast cancer -    - HIM system offers potential for significantly improved predictability in preclinical drug testing -   CAMBRIDGE, MA April 4, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company

- AV-412, a novel EGFR/HER2 kinase inhibitor, demonstrates potent anti-tumor activity against both Tarceva® and Iressa®-sensitive and resistant tumors - - AV-412 holds promise as a broader-acting EFGR/HER2 inhibitor - CAMBRIDGE, MA April 4, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical

- Dr. Ryan's Expertise in Translational Medicine a Key Addition as AVEO Moves its Portfolio of Novel Cancer Medicines Forward into the Clinic -   CAMBRIDGE, MA March 30, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer

Palo Alto, Calif. – March 30, 2006 – Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), a leading debt and equity growth capital provider to technology and life science companies, announced on March 29, 2006 it provided $15.0 million of debt financing to AVEO Pharmaceuticals, Inc., a

AVEO's Human Response Prediction Platform to Guide Clinical Development of Multiple Kinase Inhibitor   CAMBRIDGE, MA January 5, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that AVEO has